BOLZATI, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.980
EU - Europa 258
AS - Asia 189
SA - Sud America 3
AF - Africa 1
OC - Oceania 1
Totale 2.432
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.980
CN - Cina 140
IT - Italia 108
FI - Finlandia 46
VN - Vietnam 38
SE - Svezia 33
DE - Germania 25
FR - Francia 22
GB - Regno Unito 9
IN - India 6
IE - Irlanda 5
NL - Olanda 4
SG - Singapore 4
PL - Polonia 3
UA - Ucraina 3
VE - Venezuela 2
AU - Australia 1
CL - Cile 1
EG - Egitto 1
MY - Malesia 1
Totale 2.432
Salva come PNG Salva come JPEG
Città #
Fairfield 333
Chandler 253
Woodbridge 181
Houston 177
Ann Arbor 163
Ashburn 136
Seattle 106
Cambridge 104
Wilmington 97
Beijing 40
Medford 39
Princeton 39
Dong Ket 38
Padova 33
Des Moines 32
San Diego 28
Nanjing 23
Helsinki 22
Boardman 21
Roxbury 16
Los Angeles 11
Columbus 8
Milan 8
New York 8
Pune 6
Shenyang 6
Trieste 6
Dublin 5
Guangzhou 5
Hefei 5
Jiaxing 5
Legnaro 5
Nanchang 5
Changsha 4
Ferrara 4
Kunming 4
London 4
Fuzhou 3
Hebei 3
Jinan 3
Norwalk 3
Wroclaw 3
Aprilia 2
Casalecchio di Reno 2
Kreischa 2
Las Vegas 2
Montegrotto Terme 2
Sant'agostino 2
Turin 2
Verona 2
Amsterdam 1
Baltimore 1
Changchun 1
Chongqing 1
Esslingen am Neckar 1
Frankfurt am Main 1
Geislingen an der Steige 1
Giugliano in Campania 1
Hangzhou 1
Harbin 1
Hialeah 1
Hounslow 1
Huzhou 1
Islington 1
Jacksonville 1
Kharkiv 1
Kuala Lumpur 1
Lappeenranta 1
Paris 1
Pozzo 1
Prescot 1
Rockville 1
Roda 1
San Giovanni In Persiceto 1
Selvazzano Dentro 1
Taizhou 1
Tappahannock 1
Wuhan 1
Zhengzhou 1
Totale 2.040
Salva come PNG Salva come JPEG
Nome #
[99mTc][Tc(N)(DASD)(PNPn)]+ (DASD=1,4-dioxa-8-azaspiro[4,5]decandithiocarbamate, PNPn=bisphosphinoamine) for myocardial imaging: synthesis, pharmacological and pharmacokinetic studies 117
99mTc(N)-DBODC(5), a potential radiolabeled probe for SPECT of multidrug resistance: in vitro study 115
[99mTc(N)PNP]-scaffold for SPECT of multidrug resistance: Early in-vitro study 108
Folic Acid-Conjugated Europium Complexes as Luminescent Probes for Selective Targeting of Cancer Cells 102
Biologically relevant Cu2+ complexes with a tridentate phenanthroline analogue: structural properties and DNA damage 100
Pharmacological characterization of α-MSH-derivatives 95
Synthesis and Characterization of [MIII(PS)2(L)] Mixed-Ligand Compounds (M = Re,99Tc; PS = Phosphinothiolate; L = Dithiocarbamate) as Potential Models for the Development of New Agents for SPECT Imaging and Radiotherapy 92
TcIII-based mixed complexes for the design and the development of new SPECT tracers 91
A bis(thiosemicarbazone) bifunctional chelating agent for nitrido-technetium-99m and copper-64 based radiopharmaceuticals 90
Melanoma targeting with [99mTc(N)(PNP3)]-labeled α-melanocyte stimulating hormone peptide analogs: Effects of cyclization on the radiopharmaceutical properties 85
99mTc(N)-DBODC(5) from cardiology to oncology: preliminary in vitro study 84
Assessment of the best N3− donors in preparation of [M(N)(PNP)]-based (M=99mTc-; 188Re) target-specific radiopharmaceuticals: Comparison among succinic dihydrazide (SDH), N-methyl-S-methyl dithiocarbazate (HDTCZ) and PEGylated N-methyl-S-methyl dithiocarbazate (HO2C-PEG600-DTCZ) 79
Transglutaminase-mediated conjugation and nitride-technetium-99m labelling of a bis(thiosemicarbazone) bifunctional chelator 76
Insights into the failure of the potential, neutral myocardial imaging agent TcN-NOET: physicochemical identification of by-products and degradation species 75
Synthesis and characterization of rhenium(III) complexes with (Ph2PCH2CH2)2NR diphosphinoamine ligands 74
Chelating Systems for 99mTc/188Re in the Development of Radiolabeled Peptide Pharmaceuticals 69
Radiopharmacological characterization of 64Cu-labeled α-MSH analogs for potential use in imaging of malignant melanoma 66
[Re-188(N)(cys similar to)(PNP)](+/0) mixed ligand compounds as models for target specific agents 65
A bis(thiosemicarbazone) bifunctional chelating agent for Nitrido-Technetium-99m and Copper-64 based radiopharmaceuticals 64
Synthesis and Characterization of Novel Hexacoordinated, Asymmetrical M(III) (M = Re, 99gTc) Complexes as Models for the Development of Potential Tracers for SPECT Imaging and Radiotherapy 60
Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen 60
[99mTc(N)(DBODC)(5)]+: sub-cellular distribution and metabolism studies of this new potential myocardial imaging agent 58
Radiation effective dose assessment of [51Mn]- and [52Mn]-chloride 56
64Cu-Labelled compounds with dithiocarbamate ligands for theragnostic applications: preliminary in vitro studies 54
99mTc(N)(DASD)(pnpn)]+ (DASD=1,4-dioxa-8-azaspiro[4,5]decandithiocarba pnpn=bisphosphinoamine) for myocardial imaging 53
Synthesis and biological evaluation of new [Tc(N)(R2PS)]-based mixed compounds as analogues of WAY 100635 52
Synthesis and biological evaluation of new [99mTc(N)(PNPn)]2+-labeled cRGDfK peptide: preliminary studies 39
Nitrido technetium-99m core in radiopharmaceutical applications: Four decades of research 39
Synthesis and characterization of novel asymmetrical M(III) (M = Re, 99gTc) complexes as models for the development of potential tracers for SPECT imaging and radiotherapy 38
99mTc(N)-DBODC(5), a potential probe for SPECT imaging of multidrug resistance: in vitro study 35
Preclinical dosimetric studies of 177Lu-scFvD2B and comparison with 177Lu-PSMA-617 and 177Lu-iPSMA endoradiotherapeutic agents 31
[99mTc(N)(DASD)(PNPn)]+ Compounds as Myocardial Perfusion Imaging Agents. 29
Dosimetry of 51MnCl2 and 52MnCl2 for PET application 28
Synthesis a new radiopharmaceutical for prostate cancer SPECT imaging 27
Synthesis and Characterization of Novel Asymmetrical M(III) (M = Re, 99gTc) Complexes as Models for the Development of Potential Tracers for SPECT Imaging and Radiotherapy 25
Method for labeling of sensitive and thermosensitive targeting biomolecules with technetium based compounds 25
Synthesis and biological evaluation of new [99mTc(N)(PNPn)]2+-labeled cRGDfK peptide: preliminary studies 23
Conjugation and characterization of a new prostate cancer theranostic radiopharmaceutical 20
Impact of Different [Tc(N)PNP]-Scaffolds on the Biological Properties of the Small cRGDfK Peptide: Synthesis, In Vitro and In Vivo Evaluations 19
Development of a new prostate cancer theranostic radiopharmaceutical 19
Comparison of preclinical dosimetric studies of 177Lu-scFvD2B, 177Lu-PSMA-617 and 177Lu-iPSMA. 18
Zirconium immune-complexes for PET molecular imaging: Current status and prospects 11
Totale 2.466
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.308
article - articoli 6.689
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 81
selected - selezionate 0
volume - volumi 0
Totale 16.078
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019160 0 0 0 0 0 0 0 0 0 37 68 55
2019/2020480 72 9 13 45 50 29 62 63 50 45 34 8
2020/2021344 21 15 18 27 10 12 5 39 34 55 37 71
2021/2022426 16 52 43 27 21 30 23 43 18 14 33 106
2022/2023474 78 59 9 76 72 56 4 22 50 14 25 9
2023/2024248 18 51 46 20 28 23 24 11 5 22 0 0
Totale 2.466